Vaccination with HPV-18 E7–pulsed dendritic cells in a patient with metastatic cervical cancer
AD Santin, S Bellone, M Gokden… - … England Journal of …, 2002 - Mass Medical Soc
AD Santin, S Bellone, M Gokden, MJ Cannon, GP Parham
New England Journal of Medicine, 2002•Mass Medical SocTo the Editor: The management of disseminated carcinoma of the cervix that is no longer
amenable to control with surgery or radiation therapy has not improved significantly with the
advent of modern chemotherapy. The one-year survival rate remains between 10 percent
and 15 percent. 1 Studies have provided a rationale for using dendritic cells as natural
adjuvants for human immunotherapy. 2–4 We describe a 52-year-old woman with multiple
lung metastases secondary to recurrent human papillomavirus type 18 (HPV-18) …
amenable to control with surgery or radiation therapy has not improved significantly with the
advent of modern chemotherapy. The one-year survival rate remains between 10 percent
and 15 percent. 1 Studies have provided a rationale for using dendritic cells as natural
adjuvants for human immunotherapy. 2–4 We describe a 52-year-old woman with multiple
lung metastases secondary to recurrent human papillomavirus type 18 (HPV-18) …
To the Editor: The management of disseminated carcinoma of the cervix that is no longer amenable to control with surgery or radiation therapy has not improved significantly with the advent of modern chemotherapy. The one-year survival rate remains between 10 percent and 15 percent.1 Studies have provided a rationale for using dendritic cells as natural adjuvants for human immunotherapy.2–4
We describe a 52-year-old woman with multiple lung metastases secondary to recurrent human papillomavirus type 18 (HPV-18)–associated adenocarcinoma of the uterine cervix. In 1997 she underwent external irradiation and intracavitary brachytherapy combined with weekly intravenous infusions of cisplatin and followed . . .
The New England Journal Of Medicine